Principal Invetigator
Clinical Trials
Clozaril in Treatment Resistant Patients
Study #100-129-71
Approved November 1989: Sandoz
Compassionate Treatment with Fluoxamine to Outpatients with Obsessive Compulsive Disorder (Protocol # H 114-5533) Kali-Duphar Laboratories Inc. (Approved April 1988) Reid Rowell
Fluoxetine in the Treatment of Obsessive Compulsive Disorders
#56 Eli Research (Approved September 1986)
Anafranil in the Treatment of Obsessive Compulsive Disorder
Protocol #67 (Approved December 1988) Ciba Geigy
Humanitarian Extension of Fluovoxamine Beyond One Year
(Approved March 1991) Beecham Laboratories
Multicenter Trail to Evaluate the Efficacy and Safety of Sertraline in the Treatment of Major Depression, Pfizer Pharmaceuticals
Protocol #91-S-5117 (October 1991)
Zatosetron in Patients with Generalized Anxiety Disorder
Protocol # F2VMCHKAA, Eli Lilly (June 1992)
Fluovoxamine vs. Placebo in the Treatment of Panic Disorder: a Flexible Dose, Blind Study Comparing Efficacy and Safety, Upjohn Pharmaceutical Protocol #M/2315/0003 (January 1993)
Olanzapine Versus Placebo in the Treatment of Schizophrenia
Lilly Research Laboratories Protocol FID-MC-HGAP (1993)
An Open Label Assessment of the Long-Term Safety of Sertraline in the Treatment of Patients with Schizophrenia and Other Psychotic Disorders, Abbott Laboratories (1993)
(continued)
A Double-Blind Comparison of Sertindole and Haldol: An Assessment of the Chronic Safety, Efficacy, Quality of Life and Relapse in Stable Schizophrenic Patients
Abbott Laboratories (1994)
Olanzapine vs. Placebo in the Treatment of Patients with Psychosis Associated with Dementia, Lilly Research Laboratories (1994)
Phase III Six Week Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Two Fixed Doses of Oral Zisprasidone, Pfizer Pharmaceutical (1995)
A Fifty-Two Week, Open Extension Study Evaluating the Safety and Outcome of 40¬200mg Daily of Oral Zisprasidone in Subjects who have participated in previous Zisprasidone Clinical Trials, Pfizer Pharmaceuticals
Olanzapine vs. Risperdone in the Treatment of Schizophrenia and other Psychotic Disorders. Lilly Laboratories (1995)
A Multi-Center, Placebo-Controlled Study of Relapse-Prevention By Long Treatment with High or Low Doses of Org 448 in Outpatients with Recurrent Major Depressive Episodes. Organon Pharmaceuticals (1995)
Study of Olanzapine in Schizophrenic Patients discontinuing Clozapine Therapy (FID¬MC-AGDY) May 1996, Eli Lilly
Open Label Experience with Olanzapine (FID-MC-HGCY) November 1996, Eli Lilly
Olanzpine vs. Placebo in the Treatment of Mania Associated with Bipolar Disorder (FID¬MC-HGEH) November 1996, Eli Lilly.
An Open Study to Evaluate the Safety and Efficacy of 3mg a day through 12mg a day of Exelon in Patients with Mild to Severe Probable Alzheimer's Disease in the Community Setting (ENAB-356) December 1996, Novartis
An Open Label Multi-Center Trail Evaluation the Safety and Efficacy of Doneprezil Hydrochloride in Patients with Alzheimer's Disease (E2020-AOOI-313) December 1996, Pfizer/Eisar
A 24-Week, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Patients with Dementia Associated with Cerebrovascular Disease. Eiesai, Inc. April 1997
A Phase ill, Double-Blind, Placebo-Controlled Study of Aripriprazole in the Treatment of Psychosis. Otsuka, September 1997
A Multicentre, Double-Blind, Placebo Controlled, Randomized, Fixed-Dose Evaluation of the Safety and Efficacy of Laotrigine in the Long-Term Prevention of Relapse and Recurrence of Depression and/or Mania in Patients with Bipolar I Disorder. Glaxo Wellcome, September 1997
A Mutilcentre, Double-Blind, Double-Dummy, Placebo and Lithium-Controlled, Randomized, Flexible Dose Evaluation of the Safety and Efficacy of Lamotrigine in the Long-term Prevention of Relapse and Recurrence of Mania and/or Depression in Patients with Bipolar I Disorder. Glaxo Wellcome, September 1997
A Phase III Randomized study comparing 2 does of IM Ziprasidone in Subjects with Psychosis and Acute Agitation. Pfizer, August 1997
Weekly Enetric-Coated Fluoxetine-hydrochloride vs. Daily Fluoxetine or Placebo in the continuation treatment of Major Depressive Disorder. Eli Lilly, October 1997
A Double-Blind, Randomized, Multi-Center, Parallel Design Study to evaluate the Efficacy and Safety of 3 dose ranges of EMD 68 843 in comparison with Placebo and Fluoxetine in outpatients with Major Depressive Disorder. Merck KGAA, August 1997
Fluoxetine Augmentation in Schizophrenic or Schizoaffective Patients with Depressive or Negative Symptoms who are Partial or Nonresponders to Olanzapine. Eli Lilly, September 1997
A Double-Blind, Placebo and Holoperidol-Controlled, Multi-center Study Evaluation the Safety and Efficacy of SR 48692 in Schizophrenic Patients. Sanofi Pharmaceutical, June 1998
Fluoxetine vs. Placebo in Posttraumatic Stress Disorder. Eli Lilly, August 1998
A Randomized, Double-Blind, Placebo-Controlled, 12 month Safety and Efficacy Trail of ldebenone (CV-2619) 360mg TID in patients with probable Alzheimer's Disease. Takeeda, September 1998
Olanzapine vs. Haldol in the Treatment of Acute Mania. Eli Lilly, September 1998
Olanzapine vs. Placebo in the Prevention of Relapse in Bipolar Disorder. Eli Lilly May 1999
A Double-Blind, Randomized, Multi-center, Parallel Group Design to evaluate the Efficacy and Safety of 2 dose ranges of EM-D 128130 in comparison with Placebo and Haloperidol in the Treatment of Schizophrenia. Merck, January 1999
The Combination of Olanzapine and Fluoxetine in Treatment Resistant Depression without Psychotic Features. Eli Lilly, October 1999
R-Fluoxetine vs. Placebo in the Treatment of Major Depressive Disorder. Eli Lilly, January 2000
R-Fluoxetime vs. Placebo in the Treatment of Generalized Anxiety Disorder. Eli Lilly, January 2000
Protocol #RIS-USA-259 entitled "An Open Label Trial Exploring a Switching Regimen from Oral Neuroleptics, other than Risperidone, to Risperidone Microspherics" Janssen Pharmaceutical, 2001
Protocol 061-00: A Double-Blind, Mulitcenter, Placebo and Active-Controlled Acute and Extension Study of Two Doses of MK-0869 in the Treatment of Patients with Major Depressive Disorder. Merck Research Laboratories, 2001
A Double-Blind, Randomized, Placebo-Controlled 3-Month Clinical Trial of Venlafaxine ER and Sertraline in the Treatment of Posttraumatic Stress Disorder. Wyeth-Ayerst, 2001
"Dose Escalation, Double-Blind Treatment with Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in a Major Depression", Protocol FlJ-US-HMBY. Eli Lilly, 2002
A Double-Blind, Multicenter, Placebo-Controlled Study ofL-830982 Gel Extrusion Module (GEM) 1.5 mg b.i.d to 3 mg b.i.d in the Treatment of Outpatients With Generalized Anxiety Disorder (Protocol 019-00. Merck Research Laboratories, 2002
Protocol AK130927 "A Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Effects on Sexual Functioning of the Extended-Release Bupropion Hydrochloride (300-450mg) and Escitalopram (10-20 mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period." GSK, 2002
C-2002-012 titled, "A Placebo-Controlled, Double-Blind, Parallel Study of the Efficacy and Safety of Depoxatine HCI on the Treatment of Rapid Ejaculation." Alza Pharmaceuticals, 2003
A 7 Month, Multicenter, Parallel, double-Blind, Placebo-Controlled Comparison of 150¬300mg/day of Extended-Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 9-week Observational Follow-up Phase. GSK, 2004
Protocol 100368- A Twelve-week, Multicenter, Randomized, Double-blind. Double¬dummy, parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (Wellbutrin XL, 150-450 mg/day) in Subjects with Major Depressive Disorder. GSK, 2004
A Multicenter, Randomized, Parallel-group, Double-blind, Phase III Comparison of the Efficacy and Safety of Quetiapine Fumarate (oral tablets 400 mg to 800 mg daily in divided dosed) to Placebo When Used as Adjunct to Mood Stabilizers (Lithium or Divalproex) in the Maintenance Treatment of Bipolar I Disorder in Adult Patients, Protocol Number D1447C00127. Astra Zeneca, 2004
Protocol FlJ-MC-HMDV "Duloxetine 60 to 120 mg Once Daily Compared with Placebo in the Prevention of Relapse in Generalized Anxiety Disorder; Eli Lilly, 2005
1236 Park Avenue
New York City, NY 10128
(212) 722-6604
